AUM Biosciences merges with Nasdaq listed Mountain Crest

AUM is advancing a broad portfolio of precision oncology therapeutics. AUM001 is a selective and synergistic MNK inhibitor against metastatic colorectal cancer. The potential drug is expected to begin Phase 2 enrollment in the fourth quarter 2022. Its second molecule AUM601 is on track to enter Phase 2.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LAKolyz
via IFTTT